ÂÜÀòÂÒÂ×

Kevin Herde is an experienced financial management executive with over 20 years of experience in finance, accounting and general management focusing on diagnostics, biopharmaceutical development and technology. Mr. Herde joined Maravai LifeSciences from Sorrento Therapeutics, a publicly traded biopharmaceutical company, where he was most recently Executive Vice President and Chief Financial Officer. Prior to Sorrento Therapeutics, Mr. Herde served as Vice President of Global Blood Screening at Hologic. There he worked in conjunction with the company’s strategic partners at Grifols and Novartis, managing a multinational business providing molecular diagnostics solutions to improve blood safety. Mr. Herde also worked with Carl Hull and Eric Tardif as Vice President, Finance and Corporate Controller for Gen-Probe prior to its acquisition by Hologic in 2012. Mr. Herde is a CPA and began his career with KPMG. Mr. Herde holds a B.B.A. in business administration from University of San Diego.